Quelle: - pixabay.com:
Vitrolife AB: Interim report Q2, 2025: Strong performance across Consumables
GOTHENBURG, Sweden, July 17, 2025 /PRNewswire/ --
Second quarter
- Sales of SEK 871 (941) million, a flat growth in local currencies and a 7% decrease in SEK, due to a significant currency impact of -8%. Organic growth in local currencies excluding discontinued business was 3%.
- Sales per region, in local currencies was -3% in EMEA, +5% excluding discontinued business, +5% in Americas and 0% in APAC.
- Sales per product group, in local currencies excluding discontinued business was +9% in Consumables, -6% in Technologies and +3% in Genetics.
- Sales per product group, in local currencies was +5% in Consumables, -8% in Technologies and 0% in Genetics.
- Gross margin decreased to 58.0% (59.9) also negatively impacted by currency.
- Earnings before depreciation and amortisation (EBITDA) decreased to SEK 243 (327) million, resulting in an EBITDA margin of 27.8% (34.7), significantly impacted by negative currency effect.
- Operating cash flow amounted to SEK 151 million (236).
- Net income was SEK 100 (143) million, resulting in earnings per share of SEK 0.74 (1.06).
- Vitrolife AB (publ) acquired a leading stake in AutoIVF.
First half year
- Sales of SEK 1,714 (1,782) million, a flat growth in local currencies and a 4% decrease in SEK, due to a significant currency impact of -4%. Organic growth in local currencies excluding discontinued business was 3%.
- Sales per region, in local currencies was +2% in EMEA, +10% excluding discontinued business, +7% in Americas and -8% in APAC.
- Sales per product group, in local currencies excluding discontinued business was +7% in Consumables, -6% in Technologies and +4% in Genetics.
- Sales per product group, in local currencies was +4% in Consumables, -7% in Technologies and +1% in Genetics.
- Gross margin decreased to 57.7% (58.6) also negatively impacted by currency.
- Earnings before depreciation and amortisation (EBITDA) decreased to SEK 500 (600) million, resulting in an EBITDA margin of 29.2% (33.6), significantly impacted by negative currency effect.
- Operating cash flow amounted to SEK 220 million (434).
- Net income was SEK 199 (258) million, resulting in earnings per share of SEK 1.48 (1.91).
Gothenburg, July 17, 2025
VITROLIFE AB (publ)
Bronwyn Brophy O'Connor, CEO
This disclosure contains information that Vitrolife AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014) and the Swedish Securities Markets Act (2007:528). The information was submitted for publication, through the agency of the contact person, on 17-07-2025 08:00 CET.
Contact:
Amelie Wilson,
Investor Relations,
External Corporate Communications and Executive Support,
awilson@vitrolife.com
This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
| https://mb.cision.com/Main/1031/4207968/3582776.pdf | Interim report Q2, 2025 |
View original content:https://www.prnewswire.com/news-releases/vitrolife-ab-interim-report-q2-2025-strong-performance-across-consumables-302507696.html
SOURCE Vitrolife AB
Für dich aus unserer Redaktion zusammengestellt
Hinweis: ARIVA.DE veröffentlicht in dieser Rubrik Analysen, Kolumnen und Nachrichten aus verschiedenen Quellen. Die ARIVA.DE AG ist nicht verantwortlich für Inhalte, die erkennbar von Dritten in den „News“-Bereich dieser Webseite eingestellt worden sind, und macht sich diese nicht zu Eigen. Diese Inhalte sind insbesondere durch eine entsprechende „von“-Kennzeichnung unterhalb der Artikelüberschrift und/oder durch den Link „Um den vollständigen Artikel zu lesen, klicken Sie bitte hier.“ erkennbar; verantwortlich für diese Inhalte ist allein der genannte Dritte.